"Designing Growth Strategies is in our DNA"
Celiac Disease is a type of autoimmune disease which generally occurs due to ingestion of gluten that is present in wheat, rye, and barley. Celiac disease can lead to severe damage to the small intestine and with other serious complications. The disease is also called as gluten-sensitive enteropathy, celiac sprue, and non-tropical sprue. Nausea and vomiting, abdominal pain, bloating and gas, weight loss, and fatigue are some of the symptoms of celiac disease. According to the Celiac Disease Foundation, globally, an estimated 1 out of 100 people get affected by celiac disease each year.
At the present situation, there is no drug available to cure celiac disease, however, ingestion of gluten-free food and medicines are widely recommended over the world in order to prevent the occurrence of celiac disease.
Pharmaceutical companies and other drug manufacturers are prominently focusing on studying and developing new treatment options for the celiac disease. For instance; Nexvax2, which is being studied by ImmusanT, Inc, is currently in phase-2 clinical trials to check its efficacy and tolerability for the treatment of celiac disease.
To know how our report can help streamline your business, Speak to Analyst
At present around 75% of the pipeline candidates for celiac disease are in the phase-1 and phase-2 stage. Majority of the studies have been sponsored by pharmaceutical companies.
The report on ‘Celiac Disease – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Celiac Disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Celiac Disease.
The report on ‘Celiac Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
US +1 833 909 2966 ( Toll Free )